10x Genomics (NASDAQ:TXG) Price Target Raised to $19.00

10x Genomics (NASDAQ:TXG) had its target price lifted by Canaccord Genuity Group from $16.00 to $19.00 in a research note released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages also recently commented on TXG. Zacks Research raised shares of 10x Genomics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. UBS Group increased their price target on shares of 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Friday. Piper Sandler assumed coverage on shares of 10x Genomics in a report on Thursday, September 11th. They issued a “neutral” rating and a $15.00 price objective for the company. JPMorgan Chase & Co. increased their target price on 10x Genomics from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Friday. Finally, Wall Street Zen raised 10x Genomics from a “hold” rating to a “buy” rating in a report on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and a consensus price target of $14.58.

10x Genomics Stock Up 17.3%

TXG stock opened at $15.25 on Friday. The business has a 50 day moving average of $12.81 and a 200 day moving average of $11.79. The firm has a market cap of $1.90 billion, a PE ratio of -24.60 and a beta of 2.13. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $17.25.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.05. 10x Genomics had a negative return on equity of 11.71% and a negative net margin of 11.89%.The business had revenue of $149.00 million for the quarter, compared to the consensus estimate of $142.50 million. During the same period in the previous year, the company posted ($0.30) earnings per share. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. 10x Genomics has set its Q4 2025 guidance at EPS. On average, research analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares in the company, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Benjamin J. Hindson sold 7,486 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 39,149 shares of company stock valued at $539,865. Company insiders own 10.03% of the company’s stock.

Institutional Investors Weigh In On 10x Genomics

Large investors have recently made changes to their positions in the company. Allworth Financial LP lifted its stake in shares of 10x Genomics by 150.4% in the 2nd quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after purchasing an additional 1,364 shares during the period. GAMMA Investing LLC increased its holdings in 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock valued at $31,000 after buying an additional 1,614 shares during the last quarter. Signaturefd LLC raised its position in 10x Genomics by 134.3% in the first quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock worth $37,000 after acquiring an additional 2,409 shares during the period. Whittier Trust Co. purchased a new position in shares of 10x Genomics during the 1st quarter worth $41,000. Finally, True Wealth Design LLC boosted its stake in shares of 10x Genomics by 1,552.5% during the 2nd quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after acquiring an additional 3,369 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.